Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40498 Century Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Introduction & Executive Summary [CEO's Strategic Overview](index=1&type=section&id=CEO's%20Strategic%20Overview) The CEO outlined strategic priorities to focus capital on transformative cell therapy candidates and accelerate key programs - Strategic focus on potentially transformational cell therapy candidates and technologies[3](index=3&type=chunk) - Continued clinical execution of **CNTY-101** in autoimmune disease and acceleration of core preclinical programs[3](index=3&type=chunk) - IND-enabling studies are underway for **CNTY-308**, with rapid progress toward drug candidacy for the non-immune cell program[3](index=3&type=chunk) - **Brent Pfeiffenberger**, CEO, assumed the role of Board Chair, succeeding Joe Jimenez[3](index=3&type=chunk) [Key Highlights](index=1&type=section&id=Key%20Highlights) Q2 2025 highlights include ongoing CNTY-101 patient dosing, CNTY-308's advancement, a CEO leadership change, and an extended cash runway - Patient dosing is ongoing in the **CALiPSO-1 trial** for CNTY-101, with clinical data expected by **year-end 2025**[4](index=4&type=chunk) - **CNTY-308**, a CAR-iT cell therapy, is now in IND-enabling studies and is expected to progress into the clinic in **2026**[4](index=4&type=chunk) - CEO **Brent Pfeiffenberger** has been appointed to Board Chair[4](index=4&type=chunk) - Cash runway has been extended into the **fourth quarter of 2027**[4](index=4&type=chunk) Pipeline and Program Updates [CNTY-101 in Autoimmune Diseases](index=2&type=section&id=CNTY-101%20in%20Autoimmune%20Diseases) The CALiPSO-1 trial for CNTY-101 is actively enrolling patients, with initial data expected by year-end 2025 - **CALiPSO-1 trial** for CNTY-101 is progressing with continued patient enrollment and clinical trial site activations; **two patients dosed**[7](index=7&type=chunk) - Clinical data for CNTY-101 in B-cell-mediated autoimmune diseases is on track to be reported by the **end of 2025**[7](index=7&type=chunk) - **CARAMEL IIT study** activated in July, with initial patient enrollment and dosing expected in **Q3 2025**[7](index=7&type=chunk) - Preclinical data presented at EULAR 2025 Congress demonstrated CNTY-101's ability to exhibit **B cell depletion**[7](index=7&type=chunk) [CNTY-308 and Other Preclinical Programs](index=2&type=section&id=CNTY-308%20and%20Other%20Preclinical%20Program) CNTY-308 has initiated IND-enabling studies for B-cell-mediated diseases, with clinical studies planned for 2026 - **CNTY-308** initiated Investigational New Drug (IND)-enabling studies for B-cell-mediated diseases; clinical studies planned for **2026**[7](index=7&type=chunk) - Rapid progress towards drug candidacy has been made for Century's first non-immune cell therapy program engineered with **Allo-Evasion™ 5.0**[7](index=7&type=chunk) - EULAR 2025 Congress presentation supported CNTY-308's ability to deliver rapid ablation of primary B cells and **Allo-Evasion™ 5.0's** protection from allogeneic immune cells[8](index=8&type=chunk) Corporate Updates [Leadership Changes](index=3&type=section&id=Leadership%20Changes) CEO Brent Pfeiffenberger was elected Board Chair, succeeding Joe Jimenez, who transitioned to a special advisor role - **Brent Pfeiffenberger**, PharmD, Chief Executive Officer, was unanimously elected to serve as Board Chair[12](index=12&type=chunk) - **Joe Jimenez**, who served as Board Chair since 2021, transitioned to a new role as a special advisor[12](index=12&type=chunk) [Cash Runway and Strategic Focus](index=3&type=section&id=Cash%20runway%20extended) The company extended its cash runway into Q4 2027 through a workforce reduction and strategic pipeline prioritization - Cash runway extended into the **fourth quarter of 2027**[12](index=12&type=chunk) - Extension achieved through a workforce reduction in July 2025 and prioritization of pipeline development for **CNTY-101**, **CNTY-308**, and the non-immune cell program[12](index=12&type=chunk) Summary of Financial Results [Cash Position](index=3&type=section&id=Cash%20Position) The company's cash, cash equivalents, and marketable securities totaled $158.5 million as of June 30, 2025 Cash Position (in millions) | Metric | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents, and marketable securities | $158.5 | $220.1 | - The company estimates its cash, cash equivalents, and investments will support operations into the **fourth quarter of 2027**[11](index=11&type=chunk) [Operating Expenses](index=4&type=section&id=Operating%20Expenses) Operating expenses for Q2 2025 saw slight decreases in both R&D and G&A compared to the prior year period Operating Expenses (Three Months Ended June 30, in millions) | Expense Type | 2025 | 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | R&D Expenses | $26.9 | $27.2 | $(0.3) | | G&A Expenses | $7.8 | $8.3 | $(0.5) | - Decrease in R&D expenses primarily due to a reduction of personnel and manufacturing costs, offset by an increase in research and laboratory costs[14](index=14&type=chunk) [Net Income (Loss)](index=4&type=section&id=Net%20Income%20(Loss)) The company reported a net loss of $32.5 million for Q2 2025, a slight increase from the $31.2 million loss in Q2 2024 Net Income (Loss) (Three Months Ended June 30, in millions) | Metric | 2025 | 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | Net Loss | $(32.5) | $(31.2) | $(1.3) | About Century Therapeutics [Company Overview](index=4&type=section&id=Company%20Overview) Century Therapeutics is a clinical-stage biotechnology company developing iPSC-derived cell therapies for autoimmune diseases and cancer - Century Therapeutics is a clinical-stage biotechnology company developing **iPSC-derived cell therapies**[13](index=13&type=chunk) - The pipeline includes programs designed to address **autoimmune diseases and cancers**[13](index=13&type=chunk) - Commitment to developing **off-the-shelf cell therapies** to expand patient access and advance care[13](index=13&type=chunk) Forward-Looking Statements [Disclaimer and Risk Factors](index=5&type=section&id=Disclaimer%20and%20Risk%20Factors) This report contains forward-looking statements subject to significant risks and uncertainties that could cause actual results to differ - The press release contains forward-looking statements regarding clinical development plans and timelines[15](index=15&type=chunk) - These statements involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially[15](index=15&type=chunk) - The company does not plan to publicly update or revise any forward-looking statements unless required by applicable law[15](index=15&type=chunk) Financial Statements (Detailed) [Condensed Balance Sheets](index=6&type=section&id=Condensed%20Balance%20Sheets) Total assets decreased to $284.7 million while total liabilities fell significantly to $74.8 million as of June 30, 2025 Condensed Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | December 31, 2024 | Change (vs. Dec 31, 2024) | | :--- | :--- | :--- | :--- | | Cash and cash equivalents | $56,878 | $58,441 | $(1,563) | | Short-term investments | $98,965 | $130,851 | $(31,886) | | Total current assets | $160,169 | $194,051 | $(33,882) | | Long-term investments | $2,690 | $30,818 | $(28,128) | | Total assets | $284,692 | $353,216 | $(68,524) | | Deferred revenue, current | $- | $109,164 | $(109,164) | | Total current liabilities | $14,948 | $129,782 | $(114,834) | | Total liabilities | $74,794 | $191,854 | $(117,060) | | Total stockholders' equity | $209,898 | $161,362 | $48,536 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20consolidated%20statements%20of%20operations) The company reported a net income of $44.0 million for the first six months of 2025, driven by significant collaboration revenue Condensed Consolidated Statements of Operations Highlights (in thousands, except per share amounts) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $- | $771 | $109,164 | $1,625 | | Research and development | $26,859 | $27,220 | $53,439 | $50,641 | | General and administrative | $7,805 | $8,306 | $16,212 | $17,052 | | Total operating expenses | $34,664 | $35,526 | $69,651 | $67,693 | | Net income (loss) | $(32,541) | $(31,207) | $44,019 | $(59,269) | | Net income (loss) per common share Basic | $(0.38) | $(0.38) | $0.51 | $(0.82) |

Core Insights - Century Therapeutics reported significant progress in its pipeline, focusing on cell therapy candidates for autoimmune diseases and cancer, with ongoing clinical trials and preclinical studies [2][5][6] Financial Results - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $158.5 million, down from $220.1 million at the end of 2024, with an estimated cash runway extending into the fourth quarter of 2027 [13][12] - Research and Development (R&D) expenses for Q2 2025 were $26.9 million, slightly lower than $27.2 million in Q2 2024, while General and Administrative (G&A) expenses decreased to $7.8 million from $8.3 million in the same period [13][20] - The net loss for Q2 2025 was $32.5 million, compared to a net loss of $31.2 million in Q2 2024 [13][20] Pipeline Development - CNTY-101 is currently in a Phase 1 trial (CALiPSO-1) for B-cell-mediated autoimmune diseases, with patient dosing ongoing and clinical data expected by year-end 2025 [5][6] - CNTY-308 is advancing through IND-enabling studies as a potential treatment for B-cell-mediated diseases, with plans to initiate clinical studies in 2026 [4][7] Corporate Updates - Brent Pfeiffenberger has been appointed as Board Chair, succeeding Joe Jimenez, who will continue as a special advisor [2][12] - The company has made strategic decisions to focus on high-potential programs, including a workforce reduction to align resources with its pipeline development activities [12][5]

Core Viewpoint - Century Therapeutics, Inc. has been upgraded to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The recent upgrade for Century Therapeutics indicates a positive outlook for its earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - Analysts have raised their earnings estimates for Century Therapeutics, with the Zacks Consensus Estimate increasing by 76.4% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions [10].

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investing can be risky as stocks may lose momentum if future growth does not justify high valuations [1] - Identifying the right entry point for fast-moving stocks is challenging, and traditional momentum parameters may not always be reliable [1] Group 2: Bargain Stocks and Screening - Investing in bargain stocks with recent price momentum may be a safer strategy [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) shows a four-week price change of 2.9%, indicating growing investor interest [3] - IPSC has gained 11.1% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.78, suggesting it moves 78% more than the market in either direction [4] Group 4: Valuation and Earnings Estimates - IPSC has a Momentum Score of B, indicating a favorable time to invest [5] - The stock has a Zacks Rank 2 (Buy) due to upward revisions in earnings estimates, which attract more investors [6] - IPSC is trading at a Price-to-Sales ratio of 0.45, suggesting it is undervalued at 45 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides IPSC, there are other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria, presenting further investment opportunities [7] - Zacks offers over 45 Premium Screens tailored to different investing styles to help identify winning stock picks [8]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lead to limited upside or downside risks [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) has shown a price increase of 5.9% over the past four weeks, indicating growing investor interest [4] - The stock has gained 31.6% over the past 12 weeks, with a beta of 1.77, suggesting it moves 77% more than the market [5] - IPSC has a Momentum Score of A, indicating a favorable time to invest based on its momentum [6] Group 3: Earnings Estimates and Valuation - An upward trend in earnings estimate revisions has contributed to IPSC earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects [7] - IPSC is trading at a Price-to-Sales ratio of 0.45, suggesting it is undervalued at 45 cents for each dollar of sales, providing room for growth [7] Group 4: Additional Investment Opportunities - Besides IPSC, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Group 1: Momentum Investing Overview - Momentum investing contrasts with the traditional "buy low and sell high" strategy, focusing instead on "buying high and selling higher" to capitalize on fast-moving stocks [1] - Identifying the right entry point for trending stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] Group 2: Investment Strategy - Investing in bargain stocks that have recently shown price momentum may be a safer approach [2] - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced fast-moving stocks [2] Group 3: Century Therapeutics, Inc. (IPSC) Analysis - Century Therapeutics, Inc. (IPSC) has shown a price increase of 8.3% over the past four weeks, indicating growing investor interest [3] - IPSC has gained 0.8% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 1.77, suggesting it moves 77% higher than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - IPSC has a Momentum Score of A, suggesting it is an opportune time to invest in the stock [5] - The stock has a Zacks Rank 2 (Buy) due to upward trends in earnings estimate revisions, which attract more investor interest [6] - IPSC is trading at a Price-to-Sales ratio of 0.42, indicating it is relatively cheap at 42 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - IPSC has significant potential for growth, and there are other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify winning stock picks [8]

Core Insights - Century Therapeutics, Inc. is set to present at the EULAR 2025 Congress, showcasing its preclinical cell therapy pipeline targeting autoimmune diseases and cancer [1][2] Presentation Details - The first presentation will focus on CNTY-101, an iPSC-derived allogeneic CD19 targeting CAR-NK product, demonstrating significant B cell depletion and potential for B cell-driven autoimmune diseases [2] - The second presentation will cover the generation of various iPSC-derived CAR-NK, γδ CAR-T, and αβ CAR-T cells, highlighting their effectiveness in treating B cell-mediated autoimmune diseases [2] Company Overview - Century Therapeutics is a clinical-stage biotechnology company specializing in iPSC-derived cell therapies aimed at autoimmune diseases and cancers, leveraging cellular reprogramming and genetic engineering [3] - The company aims to develop off-the-shelf cell therapies to enhance patient access and improve treatment outcomes in autoimmune disease and cancer care [3]

Group 1 - Century Therapeutics reported quarterly earnings of $0.89 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.31 per share, and improving from a loss of $0.45 per share a year ago, resulting in an earnings surprise of 387.10% [1] - The company achieved revenues of $109.16 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 139.84%, compared to revenues of $0.86 million in the same quarter last year [2] - Century Therapeutics has outperformed consensus EPS estimates for four consecutive quarters and has topped consensus revenue estimates three times in the last four quarters [2] Group 2 - Despite the positive earnings report, Century Therapeutics shares have declined approximately 51.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $10.29 million, and for the current fiscal year, it is -$1.10 on revenues of $73.35 million [7] Group 3 - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 26% of over 250 Zacks industries, suggesting a favorable outlook for companies within this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

PART I. FINANCIAL INFORMATION [Unaudited Consolidated Financial Statements](index=6&type=section&id=Item%201.%20Unaudited%20Consolidated%20Financial%20Statements) The company achieved a net income of **$76.6 million** in Q1 2025, largely due to **$109.2 million** in collaboration revenue recognition Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $51,865 | $58,441 | | Total investments | $133,969 | $161,669 | | Total current assets | $169,631 | $194,051 | | Total assets | $315,609 | $353,216 | | Deferred revenue, current | $0 | $109,164 | | Total liabilities | $75,170 | $191,854 | | Total stockholders' equity | $240,439 | $161,362 | Consolidated Statement of Operations Highlights (in thousands, except per share data) | Account | Three Months Ended Mar 31, 2025 | Three Months Ended Mar 31, 2024 | | :--- | :--- | :--- | | Collaboration revenue | $109,164 | $855 | | Research and development | $26,580 | $23,421 | | General and administrative | $8,408 | $8,743 | | Income (loss) from operations | $74,176 | $(31,309) | | Net income (loss) | $76,560 | $(28,062) | | Net income (loss) per share, basic & diluted | $0.89 | $(0.45) | Consolidated Statement of Cash Flows Highlights (in thousands) | Activity | Three Months Ended Mar 31, 2025 | Three Months Ended Mar 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(34,623) | $(30,248) | | Net cash provided by investing activities | $27,930 | $11,541 | | Net cash provided by financing activities | $120 | $18,195 | | Net decrease in cash, cash equivalents, and restricted cash | $(6,573) | $(512) | [Notes to Unaudited Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) Notes detail financial health, strategic changes, and obligations, including the Bristol-Myers Squibb collaboration termination and Clade Therapeutics acquisition - The company projects sufficient cash and financial resources, totaling **$185.8 million** as of March 31, 2025, to fund operations for at least the next 12 months[27](index=27&type=chunk) - Termination of the Bristol-Myers Squibb collaboration on March 12, 2025, led to a **$109.2 million** deferred revenue recognition in Q1 2025, with no future revenue expected[83](index=83&type=chunk)[86](index=86&type=chunk)[158](index=158&type=chunk) - The April 2024 acquisition of Clade Therapeutics added three preclinical programs, but its **$4.3 million** goodwill was fully impaired by December 31, 2024[62](index=62&type=chunk)[67](index=67&type=chunk) - Future contingent milestone payments include up to **$16.1 million** per product to Distributed Bio, up to **$74.25 million** to iCELL Inc., and **$30 million** related to Clade/Gadeta acquisitions[88](index=88&type=chunk)[90](index=90&type=chunk)[91](index=91&type=chunk)[93](index=93&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=30&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses pipeline re-prioritization, the impact of the Bristol-Myers Squibb collaboration termination, increased R&D expenses, and projected cash runway into Q4 2026 - The company re-prioritized its pipeline in March 2025, discontinuing the CNTY-101 lymphoma trial to focus on B-cell mediated autoimmune diseases and three core preclinical iT cell programs[131](index=131&type=chunk)[132](index=132&type=chunk)[135](index=135&type=chunk) - The Bristol-Myers Squibb collaboration termination on March 12, 2025, resulted in a **$109.2 million** revenue recognition in Q1 2025[141](index=141&type=chunk)[158](index=158&type=chunk) R&D Expense Breakdown (in thousands) | Component | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Personnel and related costs | $9,984 | $9,761 | $223 | | Facility and other allocated costs | $5,322 | $4,692 | $630 | | Research and laboratory | $9,475 | $8,042 | $1,433 | | Other | $1,799 | $926 | $873 | | **Total R&D Expense** | **$26,580** | **$23,421** | **$3,159** | - Cash, cash equivalents, and investments of **$185.8 million** as of March 31, 2025, are projected to fund operations into Q4 2026, supported by a **$60 million** private placement in April 2024[134](index=134&type=chunk)[162](index=162&type=chunk)[165](index=165&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its **$188.6 million** investment portfolio, with no material impact expected due to low-risk instruments - The company faces interest rate risk on its **$188.6 million** cash and investment portfolio, though material impact is not anticipated due to low-risk instruments[184](index=184&type=chunk)[186](index=186&type=chunk) - Potential disruptions in financial institutions pose a risk to the company's access to cash and cash equivalents[187](index=187&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal controls during the quarter - Disclosure controls and procedures were deemed effective at a reasonable assurance level by management as of March 31, 2025[189](index=189&type=chunk) - No material changes to internal control over financial reporting occurred during the quarter ended March 31, 2025[190](index=190&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to materially impact its financial condition or operations - Management believes no pending claims or actions will materially adversely affect the company's operations, financial condition, or cash flows[192](index=192&type=chunk) [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's risk factors have occurred since the Annual Report on Form 10-K for December 31, 2024 - No material changes to the company's risk factors have occurred since the Annual Report on Form 10-K for December 31, 2024[193](index=193&type=chunk) [Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%2C%20Use%20of%20Proceeds%2C%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company reported no unregistered sales or repurchases of equity securities during the first quarter of 2025 - No unregistered sales of equity securities occurred during the reporting period[194](index=194&type=chunk) - The company did not repurchase any of its equity securities during the quarter[195](index=195&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during the first quarter of 2025 - No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during the quarter ended March 31, 2025[198](index=198&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including officer certifications and Inline XBRL data